Home/News/Sun Biotech Selects Exothera for the Development of an Innovative Zika Virus Process
Sun Biotech Selects Exothera for the Development of an Innovative Zika Virus Process
2024-12-19

We are proud to announce that Singapore-based Sun Biotech has initiated a collaboration with Exothera to support the development of an innovative upstream process for Zika virus production.

This exciting collaboration will utilize adherent Vero cells in the scale-X™ hydro 2.4 m² fixed-bed bioreactor, with plans to scale up to the scale-X™ carbo 30 m² bioreactor. Process development and scaling will take place at Exothera, followed by a seamless tech transfer to Sun Biotech for future operations.

Cédric Volanti, CEO of Exothera, shared:
"We are thrilled to collaborate with Sun Biotech on this forward-thinking project. Leveraging our expertise and cutting-edge technologies, we aim to accelerate the development of this critical process and contribute to advancing global health solutions."

Hyun Soo Kim, CEO of Sun Biotech, commented:
"Partnering with Exothera marks an important step in our efforts to advance Zika virus production. Exothera’s technical capabilities and collaborative approach make them the ideal partner for developing this innovative process."

This partnership highlights the commitment of both companies to delivering groundbreaking solutions for the vaccine industry. Keep an eye out for updates as we progress on this impactful project.

 

About Sun Biotech

Sun Biotech is a comprehensive vaccine company based in Singapore, dedicated to biological products innovation, registration and commercialization worldwide. We continuously pursue product development fostered by our drive to contribute to public health, minimizing health disparities through a variety of safe and high-efficacy preventive vaccines while keeping them sustainably affordable. For more information, visit www.sunbiotech.com.sg.

 

About Exothera

Exothera is an end-to-end CDMO partner delivering pre and early clinical process development, manufacturing optimization and CMC support for viral vector and RNA therapeutics and vaccines. We assist clients from start to scale, up to GMP manufacturing, including analytical testing and regulatory consultation. Thanks to our game changing technologies and experienced team, we help bring innovative therapies from bench to patient with quality, at speed and cost-effectively. For more information, visit www.exothera.world.